GlassScriptPhysician profile
Michael Allan Collins
NPI 1770593063
$6,926.21
in general payments reported to CMS, 2019-2025
47 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $644 · 2021: $743 · 2022: $442 · 2023: $955 · 2024: $1,525 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892 · Education: $37.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,892.10 |
| Education | $37.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,567.40 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novartis Pharmaceuticals Corporation | $680.31 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $677.66 | 2019-2025 | Jynarque, Abilify Mycite |
| Vifor Pharma, INC. | $397.92 | 2019-2023 | Veltassa, Korsuva |
| Amgen INC. | $357.40 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $260.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biogen, INC. | $252.36 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| E.R. Squibb & Sons, L.L.C. | $249.67 | 2020-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $207.38 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $200.58 | 2019-2022 | |
| Abbvie INC. | $193.61 | 2021-2023 | Ubrelvy |
| Travere Therapeutics, INC. | $166.71 | 2024-2025 | Filspari |
| Fresenius USA Marketing, INC. | $155.88 | 2019-2024 | Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.72 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $142.76 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.